AUSTIN, Texas, Sept. 3, 2013 /PRNewswire/ -- Spindletop Capital, a healthcare-focused investment firm, has announced the launch of five stock market indices tracking healthcare sectors.
"The focus of our Spindletop™ stock indices is to complement our current investment strategy," says Dr. Evan Melrose, Managing Director of Spindletop Capital. "In an effort to better track healthcare performance and the rotations of various healthcare segments for our partners, we have created several Spindletop Indices. Our best performing index, the Spindletop™ US Biotechnology Index, is up 35.0% YTD." Year to date, the indices have outperformed the S&P by an average of 8.5%.
"Over 100 years ago, the discovery of oil at Spindletop signaled the beginning of the oil boom in Texas," adds Dr. Melrose. "We believe the next 'Spindletop' for Texas will be healthcare tracked by the Spindletop™ Texas Healthcare Index, which is up 13.8% YTD."
The following Spindletop™ stock indices track different sectors of healthcare:
Spindletop™ US Medical Device Index (up 21.4% YTD)
Spindletop™ US Biotechnology Index (up 35.0% YTD)
Spindletop™ US Pharmaceutical Index (up 8.5% YTD)
Spindletop™ US Healthcare Services Index (up 26.8% YTD)
Spindletop™ Texas Healthcare Index (up 13.8% YTD)
Each index contains a portfolio of 25 or more stocks that meet the criteria set by Spindletop Capital's proprietary algorithms.
Spindletop Capital, founded in 2011, is a healthcare investment firm focused on providing expansion capital for commercial stage healthcare companies. Based in Austin, Spindletop is managed by an unrivaled team of investment professionals and advisors with deep operating, technical, and transactional experience. Spindletop Capital leverages the organization's deep experience, broad network and proprietary access to Texas resources to create incremental value for management teams and financing syndicates. Spindletop Capital invests nationally across all sectors of healthcare including medical devices, diagnostics, healthcare services, healthcare IT, specialty pharmaceuticals and biotechnology.
SOURCE Spindletop Capital